JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CAMBRIDGE, Mass., Feb. 27, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation is scheduled for 9:20 AM ET on March 7, 2017.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
